In8Bio (INAB) Total Non-Current Liabilities (2020 - 2026)

In8Bio has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $1.1 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities fell 48.21% year-over-year to $1.1 million; the TTM figure through Jun 2026 stood at $1.1 million (down 48.21% YoY), while the FY2025 annual figure was $1.6 million, down 53.8% from the prior year.
• Total Non-Current Liabilities came in at $1.1 million for Q2 2026 at In8Bio, down from $1.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $4.5 million in Q4 2022 to a low of $1.1 million in Q2 2026.
• Average Total Non-Current Liabilities over 5 years is $2.9 million, with a median of $3.4 million recorded in 2023.
• Year-over-year, Total Non-Current Liabilities soared 185.77% in 2023 and tumbled 56.31% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $4.5 million in 2022, then decreased by 24.66% to $3.4 million in 2023, then advanced by 0.12% to $3.4 million in 2024, then sank by 53.8% to $1.6 million in 2025, then retreated by 27.83% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $1.1 million in Q2 2026, $1.3 million in Q1 2026, and $1.6 million in Q4 2025.